Development of anticancer agents by metabolic engineering

Bidragets beskrivning

Microorganisms produce thousands of complex bioactive molecules, which they use to cope with their environment and fend off competitors. Half of all antibiotics and a significant portion of anticancer agents are microbial natural products. However, many compounds currently in use in chemotherapy have serious side effects and are expensive to manufacture. The objective of this proposal is to engineer three Streptomyces strains for production of improved anticancer agents in a controlled manner. We aim to (i) produce an efficacious molecule that has not been available in Europe due to production shortages, and (ii) improve production technologies for a widely used cancer drug to allow affordable care for cancer patients world-wide. In addition, we attempt to (iii) generate an entirely novel anticancer agent that has been shown to have fewer side effects. This would allow more intense treatment regimens that could significantly improve the survival rate of cancer patients.
Visa mer

Startår

2021

Slutår

2023

Beviljade finansiering

Mikko Metsä-Ketelä Orcid -palvelun logo
250 000 €

Finansiär

Finlands Akademi

Typ av finansiering

Akademiprojekt

Övriga uppgifter

Finansieringsbeslutets nummer

340013

Vetenskapsområden

Industriell bioteknologi

Forskningsområden

Teollinen biotekniikka

Identifierade teman

microbiome, microbiology